AI assistant
Q32 Bio Inc. — Director's Dealing 2018
Apr 4, 2018
34891_dirs_2018-04-04_c3aea483-06ef-4f87-877b-655e06e4c885.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-04-02
Reporting Person: Rock Springs Capital Management LP (10% Owner)
Reporting Person: Rock Springs Capital Master Fund LP (10% Owner)
Reporting Person: Rock Springs Capital LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-04-02 | Common Stock | C | 395845 | $0.00 | Acquired | 395845 | Indirect |
| 2018-04-02 | Common Stock | P | 250000 | $16.00 | Acquired | 645845 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-04-02 | Series B Preferred Stock | $ | C | 395845 | Disposed | Common Stock (395845) | Indirect |
Footnotes
F1: The securities reported herein are held of record by Rock Springs Capital Master Fund LP ("Master Fund"). Rock Springs Capital LLC ("RSC") is the general partner of Rock Springs Capital Management LP ("RSCM") which is the investment manager to Master Fund. RSC and RSCM may therefore be deemed to have or share beneficial ownership of the securities held directly by Master Fund.
F2: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.